Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology. (Pharmaimpact)

Polyclinique Lyon Nord

Status: Enrolling

Conditions: Neoplasm

Treatments: Procedure: Pharmaceutical consultation; Procedure: Pharmaceutical consultation and follow-up

Study type: Interventional

Funder types: Other

Identifiers

NCT06980012

2024-18-PLN

Details and patient eligibility

About

The hospital pharmacist plays a vital role at the time of the patient's first prescription in a healthcare facility, to inform the patient about his or her new therapy and create a link between the hospital and the patient's home pharmacy, so that the patient can continue to receive care at home. It is also essential that the hospital pharmacy and the patient's local pharmacy work together within a reasonable timeframe. This will help improve patient care and treatment follow-up, detect any undesirable effects and optimize their management..

The aim of this prospective interventional study is to measure the benefits of pharmaceutical monitoring in healthcare institutions at the initiation of oral therapy on patient compliance, side-effect management and adherence, in comparison with patients without this monitoring.

The primary endpoint is compliance with the Girerd questionnaire.

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient suffering from an oncological pathology (excluding hematological malignancies)
• Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments).
• Patient who has not yet started treatment or who has started treatment less than 30 days
• Patient with continuation of oral therapy dispensed in pharmacies

Exclusion criteria

• Patients suffering from hematological malignancies
• Patient living in an institution or hospital
• Patient under treatment for more than 30 days
• Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment)
• Patient whose treatment after initiation is not dispensed in a pharmacy

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 2 patient groups

specialized pharmaceutical consultation and follow-up in hospitals and community pharmacies

Experimental group

Treatment:

Procedure: Pharmaceutical consultation and follow-up

specialized pharmaceutical consultation

Active Comparator group

Treatment:

Procedure: Pharmaceutical consultation